| Literature DB >> 30626104 |
Oyindamola Vivian Ojulari1, Seul Gi Lee2, Ju-Ock Nam3,4.
Abstract
Obesity is a condition associated with the accumulation of excess fat in the body, energy imbalance, lipogenesis, etc., which increases adipose tissue mass through adipogenesis and poses a health risk. Its prevalence has become an economic burden to the health care system and the world at large. One of the alternatives to tackling obesity involves the use of bioactive compounds. We critically examined the effects of Hibiscus sabdariffa extract (HSE) on various parameters associated with the development of obesity such as; the effect of HSE on body weight, the effect of HSE on lipid accumulation, cholesterol metabolism and plasma parameters, the inhibitory effect of HSE on pancreatic lipase, and the effect of HSE on adipocyte differentiation/adipogenesis. This review has gathered reports on the various anti-obesity effects of H. sabdariffa bioactive compounds in cell and animal models, as well as in humans. Available toxicology information on the consumption of H. sabdariffa revealed that its toxicity is dose-dependent and may cause an adverse effect when administered over a long period of time. Reports have shown that H. sabdariffa derived bioactive compounds are potent in the treatment of obesity with an evident reduction in body weight, inhibition of lipid accumulation and suppression of adipogenesis through the PPARγ pathway and other transcriptional factors.Entities:
Keywords: Hibiscus sabdariffa; adipogenesis; bioactive compounds; fat accumulation; lipase inhibition
Mesh:
Substances:
Year: 2019 PMID: 30626104 PMCID: PMC6337177 DOI: 10.3390/molecules24010210
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Major bioactive compound in H. sabdariffa.
| Bioactives | Chemical Formula | Studies on Obesity |
|---|---|---|
|
| ||
| Hydroxycitric acid | C6H8O8 | [ |
| Hibiscus acid | C6H6O7 | - |
| Dimethyl hibiscus acid | C8H10O7 | - |
|
| ||
| Delphinidin-3-sambubioside (hibiscin) | C26H30O16 | - |
| Cyanidin-3-sambubioside (gossypicyanin) | C26H30O15 | - |
| Cyanidin-3,5-diglucoside | C26H30O15 | - |
| Delphinidin (anthocyanidin) | C15H11O7 | [ |
|
| ||
| Hibiscitrin (hibiscetin-3-glucoside) | C21H20O14 | - |
| Gossypitrin | C21H20O13 | - |
| Quercetin | C15H10O7 | [ |
| Luteolin | C15H10O6 | [ |
|
| ||
| Chlorogenic acid | C16H18O9 | [ |
| Protocatechuic acid | C7H6O4 | [ |
| Ellagic acid | C14H6O8 | [ |
| P-Coumaric acid | C9H8O3 | [ |
| Ferulic acid | C10H10O4 | [ |
| Caffeic acid | C9H8O | [ |
Figure 1Chemical structural formula of major bioactive compounds in H. sabdariffa.
Studies on H. sabdariffa bioactive compounds and their anti-obesity effects.
| Subject | Extraction Solvent | Effective Dose | Species | Observed Effect(s) | References |
|---|---|---|---|---|---|
| Mouse | Aqueous | 33.64 mg/kg | Swiss Webste (CFW) | Suppressed body weight gain in Ob/MSG mice by 9.6% and reduces glycaemia | [ |
| Aqueous | 33 mg/kg | C57BL/6NHsd | Reduced fat tissue accumulation, normalized the glycemic index as well as reduced dyslipidemia | [ | |
| Rat | Methanol | 100 mg/kg, 200 mg/kg | Sprague-Dawley rats | Significantly reduced the plasma level of triacylglycerol cholesterol, and LDL/HDL risk ratio | [ |
| Methanol | 200 mg/kg | Sprague-Dawley rats | HPE inhibited fat deposition, hyperglycemia, serum advanced glycation end-products (AGE) | [ | |
| Aqueous and Methanol | 3% of 750 mg (22.5mg) | Wistar Rats | Prevented increase in body weight and decreased adipocytes hyperplasia on rats fed a hypercaloric diet | [ | |
| Ethanol | 5%, 10%, 15% ( | Sprague-Dawley rats | Prevented increase in body weight, triglyceride, LDL and total lipids were lowered | [ | |
| Aqueous | 100 mg/kg | Sprague-Dawley rats | Attenuated body weight gain, plasma leptin, cholesterol, triglycerol, LDL and systolic blood pressure | [ | |
| Aqueous | 500 mg/kg | Sprague-Dawley rats | Prevented the hypercholesterolemia induced by dietary fructose | [ | |
| Human | Aqueous | 1 g HSE capsule-dose | In vivo (human trial) | Decreased serum FFA level of the HSE group and improved liver steatosis | [ |
| - | 100mg (Capsule) | In vivo (clinical study) | Patients with metabolic syndrome showed a significant reduction in total cholesterol and glucose level, with increased HDL level | [ | |
| Cultured cells | Methanol | 0.25 or 0.5 mg/mL | 3T3-L1 pre-adipocytes cell | Suppressed differentiation and increased number of apoptotic cells in mature adipocytes | [ |
| Aqueous | 2 mg/mL | 3T3-L1 pre-adipocytes cell | Inhibition of lipid accumulation by reducing intracellular lipid droplet during adipogenesis | [ | |
| Aqueous | 100 mg/mL | 3T3-L1 pre-adipocytes cell | Reduced the expression of major adipogenic transcription factors including PPARγ and C/EBPα that regulate adipogenesis | [ | |
| Aqueous and ethanol | 500 µg/mL aqueous extract and ethanol extract 10 µg/mL | 3T3-L1 pre-adipocytes | Inhibited lipid accumulation and adipogenic differentiation of pre-adipocytes | [ |
Figure 2Anti-adipogenic effects on HSE through different pathways.